This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08962/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08962/identifier/kegg-drug/
n10http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB08962/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://www.drugs.com/international/

Statements

Subject Item
n2:DB08962
rdf:type
n3:Drug
n3:description
Glibornuride is a sulfonylurea-type anti-diabetic drug.
n3:group
withdrawn
owl:sameAs
n10:DB08962
dcterms:title
Glibornuride
adms:identifier
n6:DB08962 n7:D02427 n8:Glibornuride
n3:synonym
Glibornuridum Glibornurid Glibornurida Glibornuride
n3:synthesisReference
U.S. Patent 3,654,357.
foaf:page
n12:Glibornuride.html
n3:IUPAC-Name
n4:271B6046-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B604C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B604B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6048-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6049-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B604A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6045-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6052-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6053-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B604D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B604E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6050-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B604F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6051-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
26944-48-9
n3:Bioavailability
n4:271B6058-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B605A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B605B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B605C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6057-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6056-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6059-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6047-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6054-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6055-363D-11E5-9242-09173F13E4C5